Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

590 Articles

Jon C. Ogg | Jul 16, 2012 at 10:43 AM EDT

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to…

Jon C. Ogg | Jul 10, 2012 at 7:35 AM EDT

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks…

Jon C. Ogg | Jul 2, 2012 at 2:42 PM EDT

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value…

Jon C. Ogg | Jul 2, 2012 at 8:14 AM EDT

The Next Mergers & Buyouts For 2012

As of late last week we had many potentially imminent buyouts that could have hit the market. When we were…

Jon C. Ogg | Jun 30, 2012 at 9:45 AM EDT

The Long Buyout Valuation of Amylin… A Higher Price Yet To Come?

Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin…

Jon C. Ogg | Jun 5, 2012 at 8:16 AM EDT

Is Amylin Already At Full M&A Value Even Before It Is Announced? (AMLN, AZN, SNY, MRK, BMY, PFE)

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the…

Jon C. Ogg | May 18, 2012 at 7:47 AM EDT

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012…

Jon C. Ogg | Apr 27, 2012 at 9:15 AM EDT

One Big Disbelief of an Amylin Buyout… Worth Only $12 Per Share? (AMLN, BMY, MRK, AZN, SNY, PFE, NVO)

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company. It is one of the…

Paul Ausick | Apr 26, 2012 at 4:06 PM EDT

24/7 Wall St. Closing Bell (GD, ABB, HOG, COP, S, ALU, MO, PEP, TLAB, XOM, AET, BMY, BG, JBLU, LIZ, MJN, REGN, SWY, SWC, TASR, UPS, YNDX, NRGY, SPH, LEAP, AKAM)

Markets opened a few ticks lower this morning after a poor report on new claims for unemployment benefits in the…

Jon C. Ogg | Apr 23, 2012 at 2:54 PM EDT

What’s A Better Buyout: Ardea or Amylin? (RDEA, AMLN, AZN, BMY, MRK)

Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to…

Paul Ausick | Apr 23, 2012 at 7:59 AM EDT

Amylin Seeks a Buyer (AMLN, CS, GS, BMY, SNY, LLY, AZN, MRK)

Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer.…

Douglas A. McIntyre | Apr 19, 2012 at 12:09 PM EDT

Executive Pay Up 14% in 2011

The data is from a major union, and, therefore, may have a bias against chief executives. Numbers can be bent.…

Douglas A. McIntyre | Apr 5, 2012 at 6:52 AM EDT

Media Digest (4/5/2012) Reuters, WSJ, NYT, FT, Bloomberg

After legal issues slowed their progress last year, foreclosures are about to increase. (Reuters) Time Warner Cable (NYSE: TWC) may…

Jon C. Ogg | Mar 28, 2012 at 9:52 AM EDT

The Inevitable Amylin Buyout (AMLN, BMY, LLY, ALKS)

If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). …

Douglas A. McIntyre | Mar 2, 2012 at 6:37 AM EST

Media Digest (3/2/2012) Reuters, WSJ, FT, Bloomberg

Anheuser-Busch InBev NV may buy China’s Kingway Brewery Holdings’ assets. (Reuters) The Department of Justice is expected to widen its probe of mortgage-backed…

1 … 30 31 32 33 34 … 40

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The Next Mergers & Buyouts For 2012

The Long Buyout Valuation of Amylin… A Higher Price Yet To Come?

Is Amylin Already At Full M&A Value Even Before It Is Announced? (AMLN, AZN, SNY, MRK, BMY, PFE)

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

One Big Disbelief of an Amylin Buyout… Worth Only $12 Per Share? (AMLN, BMY, MRK, AZN, SNY, PFE, NVO)

24/7 Wall St. Closing Bell (GD, ABB, HOG, COP, S, ALU, MO, PEP, TLAB, XOM, AET, BMY, BG, JBLU, LIZ, MJN, REGN, SWY, SWC, TASR, UPS, YNDX, NRGY, SPH, LEAP, AKAM)

What’s A Better Buyout: Ardea or Amylin? (RDEA, AMLN, AZN, BMY, MRK)

Amylin Seeks a Buyer (AMLN, CS, GS, BMY, SNY, LLY, AZN, MRK)

Executive Pay Up 14% in 2011

Media Digest (4/5/2012) Reuters, WSJ, NYT, FT, Bloomberg

The Inevitable Amylin Buyout (AMLN, BMY, LLY, ALKS)

Media Digest (3/2/2012) Reuters, WSJ, FT, Bloomberg

FIDI’s 4.1% Yield Holds Firm as Dollar Weakness Boosts International Dividends

Why BDC Income Investors Are Facing Smaller Quarterly Checks in 2026

Monthly Gold Income of $4.43 Appeals to Retirees; Volatility Decline Threatens The Flow

A $1.8 Million 401(k) and Social Security Coming Up? Drain It Before 70 to Dodge the IRMAA Cliff

The IRS Loophole That Lets You Give Your Kids Unlimited Money Tax-Free (It's Not the $19,000 Gift Limit)

FIDI’s 4.1% Yield Holds Firm as Dollar Weakness Boosts International Dividends

Why BDC Income Investors Are Facing Smaller Quarterly Checks in 2026

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The Next Mergers & Buyouts For 2012

The Long Buyout Valuation of Amylin… A Higher Price Yet To Come?

Is Amylin Already At Full M&A Value Even Before It Is Announced? (AMLN, AZN, SNY, MRK, BMY, PFE)

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

One Big Disbelief of an Amylin Buyout… Worth Only $12 Per Share? (AMLN, BMY, MRK, AZN, SNY, PFE, NVO)

24/7 Wall St. Closing Bell (GD, ABB, HOG, COP, S, ALU, MO, PEP, TLAB, XOM, AET, BMY, BG, JBLU, LIZ, MJN, REGN, SWY, SWC, TASR, UPS, YNDX, NRGY, SPH, LEAP, AKAM)

What’s A Better Buyout: Ardea or Amylin? (RDEA, AMLN, AZN, BMY, MRK)

Amylin Seeks a Buyer (AMLN, CS, GS, BMY, SNY, LLY, AZN, MRK)

Executive Pay Up 14% in 2011

Media Digest (4/5/2012) Reuters, WSJ, NYT, FT, Bloomberg

The Inevitable Amylin Buyout (AMLN, BMY, LLY, ALKS)

Media Digest (3/2/2012) Reuters, WSJ, FT, Bloomberg

FIDI’s 4.1% Yield Holds Firm as Dollar Weakness Boosts International Dividends

Why BDC Income Investors Are Facing Smaller Quarterly Checks in 2026

Monthly Gold Income of $4.43 Appeals to Retirees; Volatility Decline Threatens The Flow

Featured Reads

A $1.8 Million 401(k) and Social Security Coming Up? Drain It Before 70 to Dodge the IRMAA Cliff

The IRS Loophole That Lets You Give Your Kids Unlimited Money Tax-Free (It's Not the $19,000 Gift Limit)